Long-lasting, targeted control over coagulation disorders powered by siRNA technology
About us
SeraGene Therapeutics is a pre-clinical stage biotech company reimagining the treatment of coagulation disorders through innovative RNA and nanomedicine technologies.
Our vision
Patients on life-long treatments deserve a life well-lived. We envision a future where coagulation disorders can be effectively managed with low treatment burden therapies.
Our technology
We are addressing limitations in current care standards for coagulation disorders by delivering innovative therapies that provide long-lasting control over disordered coagulation. Designed with life-long use in mind, we have selected high efficacy targets with a lower potential safety risk to meaningfully improve the quality of life for those living with coagulation disorders.
Our diverse portfolio of targets and technologies offer a suite of novel approaches for addressing the complex drivers of chronic diseases.
Our portfolio
Leveraging our expertise in coagulation biology and RNA technology, we hope to impact change in three key areas.
1
Developing innovative prophylactic therapies for rare bleeding disorders to provide effective treatment options that enhance patients’ quality of life.
2
Enhancing transfusable platelets for individuals with inherited or acquired platelet dysfunction.
3
Developing short and long-term prophylactic therapies for thrombotic disorders to manage thrombosis effectively while minimizing side effects.
Developing innovative prophylactic therapies for rare diseases to fill treatment gaps that have severe impacts on patients’ lives
Solving persistent problems in women's health by leveraging biological breakthroughs and the latest therapeutic technologies
Improving on prophylactic therapies for thrombotic disorders designed to break the tradeoff between safe and effective treatment
Partner with us
Help us enable a life well-lived for patients with coagulation disorders.